# 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

> **NCT00859781** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 55 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 177Lu-J591
- **DRUG:** Ketoconazole
- **DRUG:** Hydrocortisone
- **DRUG:** 111In-J591

## Key facts

- **NCT ID:** NCT00859781
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-06
- **Primary completion:** 2022-02-10
- **Final completion:** 2026-09
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00859781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00859781, "177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00859781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*